Cytokinetics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
33,717.00
14,646.00
37,501.00
16,453.00
127,790.00
106,289
Depreciation, Depletion & Amortization
433.00
490.00
589.00
741.00
1,920.00
1,239
Other Funds
7,038.00
-
-
-
-
26,771
Funds from Operations
29,766.00
10,832.00
32,363.00
24,856.00
102,246.00
78,279
Changes in Working Capital
22,048.00
34,011.00
37,246.00
12,126.00
487.00
22,936
Net Operating Cash Flow
7,718.00
44,843.00
4,883.00
36,982.00
101,759.00
101,215
Capital Expenditures
542.00
1,104.00
562.00
1,596.00
2,877.00
Sale of Fixed Assets & Businesses
13.00
-
1.00
33.00
-
Purchase/Sale of Investments
990.00
2,945.00
16,624.00
50,513.00
62,951.00
Net Investing Cash Flow
1,519.00
4,049.00
16,063.00
52,076.00
65,828.00
Issuance/Reduction of Debt, Net
-
-
14,890.00
14,996.00
1,261.00
Net Financing Cash Flow
14,488.00
48,949.00
23,915.00
16,892.00
225,919.00
Net Change in Cash
5,251.00
57.00
44,861.00
1,798.00
58,332.00
Free Cash Flow
8,260.00
45,947.00
4,321.00
35,386.00
104,636.00
Change in Capital Stock
7,450.00
48,949.00
9,025.00
1,896.00
224,658.00

About Cytokinetics

View Profile
Address
280 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.cytokinetics.com
Updated 07/08/2019
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.